Pieridae Releases Q1 2024 Financial and Operating Results and Revises 2024 Guidance
GlobeNewswire
Operating Cost Improvements & Growth in Strategic Third Party Processing Business Highlight a Solid Quarter
CALGARY,..
Operating Cost Improvements & Growth in Strategic Third Party Processing Business Highlight a Solid Quarter
CALGARY,..
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after..
· First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid..